Pontifax participates in $110m funding round in ninth deal from debut fund

Precision BioSciences will use the capital raised to extend its gene-editing technology from human therapeutics to the agri-food industry.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this